Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H1 2016', provides in depth analysis on Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted pipeline therapeutics. The report provides comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects - The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Overview 7 Therapeutics Development 8 Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Stage of Development 8 Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Therapy Area 9 Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Indication 10 Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Companies 14 Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Universities/Institutes 16 Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Assessment 18 Assessment by Monotherapy/Combination Products 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Companies Involved in Therapeutics Development 24 Merck & Co., Inc. 24 SciFluor Life Sciences, LLC 25 Tissue Therapies Limited 26 TWi Pharmaceuticals, Inc. 27 Vascular Pharmaceuticals, Inc. 28 Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Drug Profiles 29 A-11 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 AC-301 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 C-16Y - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 cilengitide - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 MK-0429 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 OCU-200 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Proagio - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 RSF-201 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 SF-0166 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 SOM-0777 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 tetraiodothyroacetic acid - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 VF-001 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 VF-002 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 VF-003 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 VF-004 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 VPI-2690B - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Dormant Projects 47 Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Discontinued Products 51 Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Featured News & Press Releases 52 May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find 52 May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology 53 Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin avß3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease 53 Feb 11, 2016: Ocugen Announces Patent Allowance For Ocu-200 54 Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update 54 Feb 25, 2013: Merck Serono Announces Phase III Trial Of Cilengitide Did Not Meet Primary Endpoint In Patients With Newly Diagnosed Glioblastoma 55 Jun 09, 2011: Merck Serono Completes Patient Enrollment For Cilengitide's Pivotal Phase III Trial CENTRIC 57 Jun 05, 2010: EMD Serono Announces Long-Term Follow-up Data From Cilengitide Study In Glioblastoma Patients 57 May 31, 2009: Study Shows Cilengitide Increased Overall Survival In Patients With Glioblastoma 58 Mar 16, 2009: Merck Serono Expands Cilengitide Development Program 59 Jan 01, 2004: 59 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 60 Disclaimer 61
List of Tables
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Comparative Analysis by Unknown Stage Development, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Products under Development by Companies, H1 2016 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Assessment by Monotherapy/Combination Products, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 23 Pipeline by Merck & Co., Inc., H1 2016 24 Pipeline by SciFluor Life Sciences, LLC, H1 2016 25 Pipeline by Tissue Therapies Limited, H1 2016 26 Pipeline by TWi Pharmaceuticals, Inc., H1 2016 27 Pipeline by Vascular Pharmaceuticals, Inc., H1 2016 28 Dormant Projects, H1 2016 47 Dormant Projects (Contd..1), H1 2016 48 Dormant Projects (Contd..2), H1 2016 49 Dormant Projects (Contd..3), H1 2016 50 Discontinued Products, H1 2016 51
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
